Based on guidelines issued by the World Health Organizations in 2018, the American College of Physicians has issued best practice advice that simplifies and improves treatment of chronic hepatitis C virus.
Measuring liver stiffness should be considered after anti-viral treatment because it predicts adverse outcomes even beyond routinely available clinical predictors.
Italian investigators conducted a prospective, multicenter study to assess the safety and effectiveness of glecaprevir/pibrentasvir in chronic hepatitis C patients and their subpopulations.
A study published in the Annals of Internal Medicine found transplanting kidneys from hepatitis C virus (HCV)-positive donors to HCV-negative recipients (HCV D+/R-) may be successful with prophylactic treatment with direct-acting antivirals.
Researchers conducted a simulated economic evaluation cohort analyses to assess the cost-effectiveness of HCV screening and compared other screening programs in the United States.
Eight weeks of treatment with glecaprevir/pibrentasvir is both efficacious and well tolerated in treatment-naive patients with HCV.
New CDC guidelines recommend a test-and-treat approach for healthcare personnel who may have been exposed to acute hepatitis C virus infection at work.
Researchers assessed changes among an aging population of people with chronic hepatitis C virus who are treated with DAAs, including the development of comorbidities and changes in liver disease severity.
By providing bundled HIV and HCV testing, substance use disorder treatment programs may create increased awareness of infection status among people with substance abuse disorders.
Men who have sex with men are more likely to receive the recommended sexually transmitted infection testing and prevention services at Ryan White HIV/AIDS Program-funded facilities.
